Advertisement
UK markets closed
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • CRUDE OIL

    78.51
    +0.03 (+0.04%)
     
  • GOLD FUTURES

    2,323.30
    -7.90 (-0.34%)
     
  • DOW

    38,848.15
    -4.12 (-0.01%)
     
  • Bitcoin GBP

    50,460.14
    +71.20 (+0.14%)
     
  • CMC Crypto 200

    1,310.10
    -55.02 (-4.03%)
     
  • NASDAQ Composite

    16,309.35
    -39.90 (-0.24%)
     
  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     

GSK, Theravance lung drug Relvar wins European green light

LONDON, Sept 19 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) and Theravance (NasdaqGS: THRX - news) 's new inhaled lung drug Relvar has been recommended for approval in Europe, Britain's biggest drugmaker said on Thursday.

The green light from the European Medicines Agency follows approval for the product in May in the United States, where it is known as Breo. The medicine is inhaled through a palm-sized device called Ellipta.